TG Therapeutics | TGTX - Assets


TG Therapeutics reported $1.64B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
AbbVie USD 135.12B 1.35B Jun/2026
Alaunos Therapeutics USD 1.88M 1.08M Mar/2026
Amgen USD 95.64B 3.14B Jun/2026
Ardelyx USD 504.51M 2.9M Mar/2026
Arrowhead Research USD 2.11B 156.25M Jun/2026
Bayer EUR 107.29B 659M Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
Corcept Therapeutics USD 888.7M 73.82M Jun/2026
Curis USD 29.69M 9.72M Mar/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
J&J USD 201.06B 167M Jun/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Novartis USD 122.03B 3.5B Jun/2026
Novavax USD 955.58M 87.59M Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
TG Therapeutics USD 1.64B 110.79M Jun/2026
Verastem USD 227.81M 18.63M Mar/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026